Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations.

被引：9
|
作者：
Varghese, Anna M.
Patel, Juber Ahamad A.
Janjigian, Yelena Yuriy
Meng, Fanli
Selcuklu, S. Duygu
Zimel, Catherine
Hyman, David Michael
Iyer, Gopa
Houck-Loomis, Brian
Abou-Alfa, Ghassan K.
Berger, Michael F.
Lowery, Maeve Aine
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA
[4] Trinity Coll Dublin, Dublin, Ireland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.4096
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4096
引用
收藏
页数：2
相关论文
共 50 条
  • [21] RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
    Subbiah, Vivek
    Sahai, Vaibhav
    Maglic, Dejan
    Bruderek, Kamil
    Toure, B. Barry
    Zhao, Songping
    Valverde, Roberto
    O'Hearn, Patrick J.
    Moustakas, Demetri T.
    Schoenherr, Heike
    Gerami-Moayed, Nastaran
    Taylor, Alexander M.
    Hudson, Brandi M.
    Houde, Damian J.
    Pal, Debjani
    Foster, Lindsey
    Gunaydin, Hakan
    Ayaz, Pelin
    Sharon, Dina A.
    Goyal, Lipika
    Schram, Alison M.
    Kamath, Suneel
    Sherwin, Cori Ann
    Schmidt-Kittler, Oleg
    Jen, Kai Yu
    Ricard, Fabien
    Wolf, Beni B.
    Shaw, David E.
    Bergstrom, Donald A.
    Watters, James
    Casaletto, Jessica B.
    CANCER DISCOVERY, 2023, 13 (09) : 2012 - 2031
  • [22] A phase II telemedicine study of pemigatinib in adult patients with unresectable or metastatic pancreas cancer with FGFR2 gene fusions or other FGFR genetic alterations.
    Risch, Zachary
    Wing, Michele
    Reeser, Julie
    Stein, Leah
    Dao, Thuy
    Smith, Amy
    Samorodnitsky, Eric
    Paruchuri, Anoosha
    Pan, Xueliang Jeff
    Roychowdhury, Sameek
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS717 - TPS717
  • [23] Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
    Brandi, Giovanni
    Relli, Valeria
    Deserti, Marzia
    Palloni, Andrea
    Indio, Valentina
    Astolfi, Annalisa
    Serravalle, Salvatore
    Mattiaccio, Alessandro
    Vasuri, Francesco
    Malvi, Deborah
    Deiana, Chiara
    Pantaleo, Maria Abbondanza
    Cescon, Matteo
    Rizzo, Alessandro
    Katoh, Masaru
    Tavolari, Simona
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [24] Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
    Giovanni Brandi
    Valeria Relli
    Marzia Deserti
    Andrea Palloni
    Valentina Indio
    Annalisa Astolfi
    Salvatore Serravalle
    Alessandro Mattiaccio
    Francesco Vasuri
    Deborah Malvi
    Chiara Deiana
    Maria Abbondanza Pantaleo
    Matteo Cescon
    Alessandro Rizzo
    Masaru Katoh
    Simona Tavolari
    Scientific Reports, 14
  • [25] A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF/FGFR alterations.
    Ciombor, Kristen Keon
    Zemla, Tyler J.
    Hubbard, Joleen M.
    Jia, Jingquan
    Gbolahan, Olumide B.
    Sousa, Andrea
    Wilson, Luke
    Waechter, Blake
    Ou, Fang-Shu
    Nixon, Andrew B.
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 139 - 139
  • [26] FGFR2 fusion and/or rearrangement profiling in Chinese patients with intrahepatic cholangiocarcinoma
    Huang, X-W.
    Shi, G-M.
    Zhang, T.
    Bao, L-Q.
    Wen, T-F.
    Zhang, B.
    Peng, T.
    Zhao, H.
    Kuang, M.
    Wang, W-L.
    Ran, J-H.
    Liu, Y-B.
    Gong, W.
    Mou, H-B.
    Luo, Y.
    Wang, Y.
    Sun, H.
    Fan, J.
    Liu, L-X.
    Dai, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S379 - S379
  • [27] A pilot study of ponatinib in cholangiocarcinoma patients with FGFR2 fusions.
    DeLeon, Thomas
    Alberts, Steven R.
    McWilliams, Robert R.
    Hubbard, Joleen Marie
    Ahn, Daniel H.
    Bekaii-Saab, Tanios S.
    Mody, Kabir
    Roberts, Lewis R.
    Salomao, Marcela
    Kipp, Benjamin
    Halfdanarson, Thorvardur Ragnar
    Murtaza, Muhammed
    Ramanathan, Ramesh K.
    Dueck, Amylou C.
    Borad, Mitesh J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [28] Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations
    Tyhonas, John S.
    Arnold, Lee D.
    Cox, Jason M.
    Franovic, Aleksandra
    Gardiner, Elisabeth
    Grandinetti, Kathryn
    Kania, Robert
    Kanouni, Toufike
    Lardy, Matthew
    Li, Chun
    Martin, Eric S.
    Miller, Nichol
    Mohan, Adithi
    Murphy, Eric A.
    Perez, Michelle
    Soroceanu, Liliana
    Timple, Noel
    Uryu, Sean
    Womble, Scott
    Kaldor, Stephen W.
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (03) : 1734 - 1746
  • [29] A murine model of FGFR2 fusion driven intrahepatic cholangiocarcinoma to delineate mechanism of therapeutic response and resistance to FGFR inhibitors
    Kendre, Gajanan
    Marhenke, Silke
    Lorz, Georgina
    Saborowski, Michael
    Vogel, Arndt
    Saborowski, Anna
    JOURNAL OF HEPATOLOGY, 2021, 75 : S249 - S249
  • [30] Non-small cell lung cancer (NSCLC) patients harboring mutations in FGFR2 and FGFR3: clinical and genomic features
    Scheffler, M.
    Chanra, T.
    Kron, A.
    Koleczko, S.
    Abdulla, D. S. Y.
    Ihle, M. A.
    Riedel, R.
    Michels, S.
    Fischer, R.
    Merkelbach-Bruse, S.
    Buettner, R.
    Nogova, L.
    Wolf, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 112 - 112
12345